收藏切换
Overview and analysis of rare disease drugs in the national drug list
收藏切换
Yunyan BI, Meng WU, Wen ZHANG, Lingjun KONG, Xianwei GONG*
World Clinical Drug | 2023, 44(10) : 1098 - 1103
Less
收藏切换
World Clinical Drug | 2023, 44(10): 1098-1103
• Review •
Overview and analysis of rare disease drugs in the national drug list
Full
Yunyan BI, Meng WU, Wen ZHANG, Lingjun KONG, Xianwei GONG*
Affiliations
  • Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong Province, China
Published: 2023-10-10 doi: 10.13683/j.wph.2023.10.014
Outline
收藏切换

In recent years, the review and approval of rare disease drugs in China has been accelerated, and the negotiation of access to the national medical insurance drug catalogue has been fully launched. Through comparative analysis of the national conversation catalogue over the years, it can be seen that from 2017 to 2022, the number of rare disease drugs included in medical insurance through national negotiations has increased from zero to 29 year by year, the time from listing to inclusion in medical insurance has been significantly shortened, and the accessibility has been significantly improved. The list of rare diseases drugs covered 16 rare disease, including 26 (89.6%) imported enterprise products and 3 (10.4%) domestic enterprise products. It reveals that although the number of rare disease drugs listed and medical insurance coverage in China have increased, the coverage of rare diseases is still small, and the research and innovation ability of domestic pharmaceutical enterprises is relatively weak. It is suggested that medical insurance, medical treatment and medicine should continue to play a synergistic role to provide sustainable impetus for the guarantee of rare disease drug use in China.

orphan drug  /  national medical insurance drugs  /  variation trend  /  feature analysis
毕云彦, 吴萌, 张文, 孔令君, 宫先卫. 国谈中罕见病用药概览与分析. 世界临床药物, 2023 , 44 (10) : 1098 -1103 . DOI: 10.13683/j.wph.2023.10.014
Yunyan BI, Meng WU, Wen ZHANG, Lingjun KONG, Xianwei GONG. Overview and analysis of rare disease drugs in the national drug list[J]. World Clinical Drug, 2023 , 44 (10) : 1098 -1103 . DOI: 10.13683/j.wph.2023.10.014
Year 2023 volume 44 Issue 10
13
0
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2023.10.014
  • Receive Date:2022-05-27
  • Online Date:2026-11-18
  • Published:2023-10-10
Article Data
Affiliations
History
  • Received:2022-05-27
Funding
Affiliations
    Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.10.014
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT